Pharmaceutical combination

Details Pharmaceutical combination Pharmaceutical combination

2005-12-13

2005-12-13

Wilson, James O. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S042000, C514S043000, C514S045000, C514S653000, C514S826000, C536S027100, C536S027130, C536S027200, C536S027210, C424S045000, C424S046000

Reexamination Certificate

active

06974803

ABSTRACT:
The present invention relates to a combination comprising (a) an adenosine A2areceptor agonist as defined herein and (b) an adrenergic β2 receptor agonist, for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease.

REFERENCES:
patent: 6143277 (2000-11-01), Ashurst et al.
patent: 6753322 (2004-06-01), Mantell et al.
patent: 2002/0058641 (2002-05-01), Mantell et al.
patent: WO9967263 (1999-12-01), None
patent: WO0194368 (2001-12-01), None
Berge et al., J. Pharm. Sci, 66, 1-19, 1977.
Sandford et al., Eur. Respir. J., 10, 1380-1391, 1997.
Thomas Giangrasso,Potential for Tolerance, Morbidity, and Mortality Resulting From Regular Use of b2-Adrenergic Agonists in Asthma, Southern Medical Journal, vol. 90, No. 2, pp. 173-179 (Feb. 1997).

Affiliated with

Also associated with

Rating

Pharmaceutical combination does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical combination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical combination will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3469734